| |
| Community Acquired Pneumonia |
Evaluation of community-acquired pneumonia (for details and addtional tests see ISDA Guidelines)
- Baseline assessment
- Chest x-ray to confirm diagnosis of pneumonia and assess severity of disease.
- For Ambulatory pts: Sputum Gram stain and culture may be useful.
- For Hospitalized pts
- Complete blood cell and differential counts
- Scr/BUN, glucose, electrolyte, and liver function indeces
- HIV serological status for pts aged 15-55 years
- Arterial blood gases and O2 for selected pts
- Blood cultures (×2; before the start of empiric antimicrobial therapy)
- Sputum Gram stain and culture.
- Acid-fast bacilli staining and culture in selected pts to test for Mycobacterium tuberculosis
- Test for Legionella in selected patients (seriously ill patients without an alternative diagnosis, especially if aged >40 years, immunocompromised, or nonresponsive to ß-lactam antibiotics, if clinical features are suggestive of this diagnosis, or in outbreak settings
- Thoracentesis for pleural fluid stain, culture, pH, and WBC count differential
Antimicrobial therapy:
- When empiric therapy is deemed necessary, the choice of the antimicrobial agent is based on the severity of illness, the most likely pathogens,
and the known resistance patterns of Strep pneumoniae, the most commonly implicated pathogen.
- When the pathogen involved is established, pathogen-specific antiinfective therapy should be started.
The antiinfective agent chosen should be the most cost-effective, least toxic, and most narrow in antimicrobial spectrum.
|
| Infection | Therapy | Comments |
| Unknown pathogen | Cefotaxime or ceftriaxone | If cephalosporin allergic, substitute erythromycin or clarithromycin |
| Influenza A | Ceftriaxone or ceftizoxime plus Amantidine or rimantidine |
| Mycoplasma or Chlamydia | Ceftriaxone or ceftizoxime plus Erythromycin or azithromycin |
| Legionella | Ceftriaxone or ceftizoxime plus Erythromycin | Substitute azithromycin if erythromycin not tolerated |
| |
| See ISDA recommendations for the treatment of community-aquired pneumonia |
| |
| Aspiration Pneumonia |
| G-negative, Anaerobes, and G-positive organisms | Cefotaxime plus Clindamycin or Zosyn or Unasyn |
| |
| Hospital Acquired Pneumonia |
| G-negatives: E. coli, Enterobacter, Pseudomonas, and Klebsiella |
Zosyn plus tobramycin or Clindamycin plus Ceftazidime or Imipenem with or without an aminoglycosides.
| >60% of nosocomial pneumonias are G-negative in origin, 15% involve Staph |
| Staphylococcus aureus | Nafcillin | If MRSA suspected, add Vancomycin |
| |
| Fungal Infections |
Blastomycosis Histoplasmosis | Itraconazole for non-life threatening, non-meningeal infections Amphotericin B for serious infections | Itraconazole requires acid pH for absorption. Avoid antacids, H2 blockers, proton-pump inhibitors
Amphotericin should be reserved for life threatening or CNS disease |
| Cryptococcus | Amphotericin B ± 5-Flucytocine | Ampho B is the agent of choice for rapidly progressing life-threatening disease Fluconazole is used for chronic suppression or prophylaxis in immunocompromised patients |
| Candida Albicans - superficial / mucosal | Fluconazole, Miconazole, Clotrimazole, and Ketoconazole | For candida esophagitis, fluconazole is the preferred agent |
| Candida albicans -deep seated / disseminated | Fluconazole or Amphotericin B | Amphotericin is the agent of choice for rapidly progressing life-threatening disease Prophylaxis with fluconazole in immunocompromised patients |
| Non-albicans candidiasis(Torulopsis glabrata, Candida krusei), deep seated, disseminated | Amphotericin B | Fluconazole is not very effective against these species |
| Candida lusetaniae | Fluconazole | Candida lusetaniae is resistant to Amphotericin |
| |
| Gastrointestinal Infections |
Cholecystitis Coliforms and enterococci | Cefotetan or Zosyn (or Unasyn) + Gentamicin | Cefotetan is used for mild-moderate infections |
Cholangitis Enterics; Enterococci; Anaerobes | Zosyn (or Unasyn) + Gentamicin | |
Diverticulitis Enterics; Anaerobes |
Cefotetan; Clindamycin + ofloxacin (or Ceftazidime); Zosyn (or Unasyn) + Gentamicin | Cefotetan is reserved for mild-moderate infections |
Intra-abdominal peritonitis or abscess Enterics; Anaerobes; Enterococci |
Zosyn (or Unasyn) + Gentamicin; Clindamycin + ofloxacin (or ceftazidime); Imipenem | |
| |
| Genitourinary Infections - UTIs |
Cystitis E. coli; Staph aprophyticus | Cotrimox; Cephalexin; Nitrofurantoin | Infection may resolve spontaneously without abx or a three-day course may be sufficient |
Pyelonephritis - Community Aquired / uncomplicated E. coli; Proteus | Cotrimox; Aminoglycosides; Ceftriaxone; Ofloxacin (oral) | Oral abx therapy is appropriate for mild-moderate cases Enterococcus is an uncommon |
Pyelonephritis - Nosocomial (underlying GU disease) E. coli; Pseudomonas; Enterococcus |
Ampicillin + gentamicin or tobramycin; Zosyn + Tobramycin; Ofloxacin ± ampicillin | These drug combinations are for empiric coverage for Pseudomonas and Enterococcus Septic patients require double G-negative coverage |
Acute Prostatitis Patient <40 yrs Neisseria gonorrhea; Chlamydia | Ceftriaxone 125 mg IM single dose or Ofloxacin 400 mg PO single dose + Doxycycline 100 mg PO bid x 7 days | |
Acute Prostatitis Patient >40 yrs Enterobacteraciae | Cotrimox or Ofloxacin | |
Chronic Prostatitis Enterobacteraciae; Enterococcus | Cotrimox for 3 months or Oflox for one month | rule out prostatic calculi in case of treatment failure |
| |
| Skin/Soft tissue Infections |
Cellulitis (non-diabetic) Streptococcus; Staphylococcus | Nafcillin or oxacillin (oral dicloxacilin) | Penicillin G is the drug of choice for known Streptococcal infection In case of PCN allergy, may use clindamycin or cefazolin ( if PCN allergy is mild). |
Decubitus ulcer / Diabetic ulcer Staphylococcus; Streptococcus; Anaerobes; G-negative organisms | Augmentin or Unasyn; Clindamycin + Ofloxacin; Zosyn ± Tobramycin | Augmentin and Unasyn are ineffective against Pseudomonas Surgical consultation should be part of routine management |
Necrotizing fasciitis Streptococcus; Staphylococcus; G-negative aerobes; Anaerobes | Penicillin + Clindamycin + Aminoglycoside (or Ofloxacin); Unasyn + Aminoglycoside (or Ofloxacin); Imipenem | Mixed flora, including anaerobes (clostridia perfringens) may be involved. Broad spectrum coverage is recommended. Primary emphasis is on surgical reatment |
Human/animal bites Pasteurella multocida; Streptococcus; Staphylococcus | Unasyn or Augmentin
| Spectrum includes Pasteurella multocida, especially in cat bites Do not use oral 1st-gen cephalosporins for Pasteurella |
| |
| Bone & Joint Infections |
Acute Osteomyelitis (hematogenous) Staphylococcus aureus; G-negatives (less frequent) | Nafcillin ± Aminoglycoside |
Appropriate cultures are essential;
G-negative osteomyelitis may be associated with underlying GI or UTI Ceftriaxone may allow outpatient parenteral therapy Cefazolin or clindamycin may be options for PCN allergic pts
|
Diabetic foot or contiguous ulcer G-negatives; G-positives; Anaerobes | Ofloxacin (PO) + Clindamycin or Zosyn / Unasyn + Aminoglycoside | Establish bacteriology with appropriate cultures whenever possible Adequate surgical debridement is critical to overall success |
| Chronic osteomyelitis | Establishing microbiology is extremely important |
Septic Arthritis in the sexually active young adult Gonococcus | Ceftriaxone 125 mg IM in a single dose or Ofloxacin 400 mg po in a single dose plus Doxycycline 100 mg po bid X 7 days | |
Septic Arthritis in older adults Staphylococcus aureus Group A; Streptococcus; G-negative aerobes | Nafcillin + gentamicin or Nafcillin + PO Ofloxacin | Microbiology needed; Orthopedic consultation required |
Septic Arthritis with prosthesis Staphylococcus epidermidis; Staphylococcus aureus; G-negatives | Vancomycin + 3rd gen cephalosporin | Orthopedic consultation required |
| |
| CNS Infections |
| Meningitis |
Community- Aquired Meningitis Age18-50 yrs Streptococcal pneumonia; N. meningitis; Haemophilus influenza (<5%)
| Cefotaxime | 3rd gen cephalosporins are empiric drug of choice due to concerns of moderately resistant pneumococcus Penicillin may be used if organism is penicillin-sensitive Antimicrobial therapy should be initiated within 30-60 min of presentation Penicillin-allergic patients should receive chloramphenicol |
Community- Aquired Meningitis
Age >50 or Alcoholic or DebilitatedG-negative aerobes; Strep. pneum.; Listeria | Ampicillin + ceftriaxone | |
| Post-surgical Meningitis
Staphy epidermis; MRSA; G-negative aerobes | Vancomycin + Ceftazidime | Infected catheters should be removed |
Meningitis in immunosuppressed host
community- aquired pathogens; Listeria Monocytogenes; fungal; mycobacterial | Ampicillin + ceftriaxone | Initial Gram stain may provide clues for likely pathogen Need to rule out cryptococcus or other opportunistic infections |
| Viral Encephalitis / Meningioencephalitis
Herpes simplex; Enteroviruses; Coxsackie | Acyclovir (for herpes)
No therapy for the others | Early initiation of IV acyclovir is important for all patients suspected to have viral encephalitis Bacterial cerebritis expected if contiguous focus, ie., mastoiditis, sinusitis, otitis media Legionella or mycoplasma may present with encephalopathy |
| Encephalitis in immunosuppressed host |
| Herpes Simplex | Acyclovir | Need to rule out cryptococcus or toxoplasmosis before empiric therapy |
| Enteroviruses | No therapy |
| Coxsackie | No therapy |
| Cryptococcus | Amphotericin B |
| Toxoplasmosis | Pyrimethamine + sulfadiazine |
| Listeria | Ampicillin |
| Brain Abscess |
Otogenic (temporal, parietal, cerebellar) Enterobacteraciae; Anaerobes; Strep. species |
Ceftriaxone + metronidazole ± Penicillin G | If endocarditis (Staph aureus) is suspected, nafcillin should be used instead of Pen G. |
| Paranasal (frontal) Enterobacteraciae | Cefotaxime | |
| |
| Head and Neck Infections |
| Acute Sinusitis Strep. pneumoniae; H. influenza; Moraxella atarrhalis | Co-trimox; Cefpodoxime; Augmentin | Need to consider fungal etiology in certain patient populations (neutropenic, transplant, or IDDM) |
| Chronic Sinusitis Staph; Strep. pneumoniae; H. influenza; Moraxella atarrhalis; Anaerobes |
Augmentin | Chronic sinusitis requires surgical drainage |
| Hospital-acquired Sinusitis Gram-negative aerobes; Staph. aureus; Anaerobes |
See pneumonia treatment | Nasotracheal intubation and nasogastric tubes may increase risk of hospital-acquired sinusitis |
| Exudative Pharyngitis Group A strep | Penicillin G | Mononucleosis may present with exudative pharyngitis |
| Vesicular/Ulcerative Pharyngitis Coxsackie, Echo, or Herpes simplex virus |
Acyclovir (for herpes simplex) | |
| Membraneous Pharyngitis Mononucleosis; Diphtheriae | Erythromycin for Diphtheriae | Endotracheal intubation for maintenance of airway Steroids for impending airway obstruction
There is no therapy for Mononucleosis |
| Epiglottitis Group A strep or Haemophilus influenza | Cefuroxime or ceftriaxone | Early elective endotracheal intubation |
| Periorbital/Orbital Cellulitis Strep species; Staph; Haemophilus influenza (adults); Anaerobes (if related to dental procedures) | Cefuroxime; Unasyn | R/O dental or sinus focus; If immunosuppressed, fungal etiology must be considered |
| Otitis media Strep. pneumoniae; H. influenza; Moraxella atarrhalis | Co-trimox; Cefpodoxime; Augmentin | Consider ENT pathology in adults with recurrent otitis media |
| Acute Mastoiditis Strep. pneumoniae; Strep. pyrogenes; Staph. aureus | Dicloxacillin; Cefuroxime | Surgery for abscess or osteomyelitis |
| Chronic Mastoiditis Polymicrobial, including Pseudomonas; Staph.aureus and anaerobes | Ceftazidime + Clindamycin; Tobramycin + Zosyn | Surgery is required |
| |
| Sexually Transmitted Diseases (STD ) |
| Urethritis / Cervicitis / Prostatitis N. gonorrhaeae; Chlamydia | Ceftriaxone 125 mg IM single dose or Ofloxacin 400 mg PO single dose plus Doxycycline 100 mg PO bid x 7 days | |
| Disseminated N. gonorrhaeae | Ceftriaxone 1 g q12 hrs for 4 doses then switch to Ofloxacin 400 mg PO qday for 7 days | |
| Pelvic Inflammatory Disease (PID) Gonococcus; Chlamydia; Bacteroides; Enteric G-negatives | Outpatient - Ceftriaxone 250 mg IM + doxycycline PO bid for 14 days
Inpatient - Cefotetan 2 g q 12 IV + doxycycline bid for 14 days | Candidates for outpatient: temp <38 °C, WBC <11,000, no indication of peritonitis |
| Genital lesions |
| Herpes Simplex / HSV | Acyclovir | |
| Chancroid Hemophilus ducreyi | Ceftriaxone 250 mg IM single dose or Azithromycin 1 g PO single dose | |
| Lymphogranuloma venereum Chlamydia | Doxycycline 100 mg PO bid x 21 days | This disease is rare in the USA |
Syphillis Primary / Secondary / Latent < 1 yrTreponema pallidum | Benzathine PCN 2.4 million units IM single dose |
HIV patients and pregnant patients with syphilis should have infectious disease consults
Benzathine PCN 2.4 million units dose should be divided in two injection sites |
Syphillis Latent > 1 yr or unknown durationTreponema pallidum | Benzathine PCN 2.4 million units IM once a week x 3 doses |
| Neurosyphilis Treponema pallidum | Penicillin G 2 - 4 million units q 4 hrs x 14 days (2-4 mu q 4 hr) |